Below is the information acquired on GILEAD SCIENCES INC, which is not yet included in our research perimeter.

To request an evaluation of this company and its inclusion in the OpenCorporation Ranking or if you have additional, different and more updated data than what is published in this OpenCorporation company card, please write to info@opencorporation.org so that our team may take it in account.

Last update 28 May 2020

Description of economic activities

Manufacture of pharmaceutical preparations (NACE2 2120)

This American biopharmaceutical company is focused on the discovery, development and commercialization of innovative medicines in areas of unmet needs. Founded in 1987, its corporate headquarters as well as its main production facility is located in Foster City, California. The company is one of the largest biopharmaceutical companies in the world, with a rapidly expanding product portfolio and a growing pipeline of investigational drugs. With each new discovery and experimental drug candidate, it aims to improve the care of patients suffering from life-threatening diseases around the world. Its portfolio of 14 marketed products includes a number of category firsts, including the only complete treatment regimens for HIV infection available in a once-dailysingle pill - Atripla (approved in 2006) and Complera (approved in 2011). In addition to its HIV drugs, the company offers drugs for liver disease (Viread and Hepsera), cardiovascular drugs (Letairis, Lexiscan, and Ranexa), respiratory drugs (Tamiflu and Cayston), amphotericin B liposome for injection (AmBisome), pegaptanib sodium injection (Macugen), and antiviral injection for cytomegalovirus retinitis (Vistide). The company has additional operations in Palo Alto and San Dimas (California), Branford (Connecticut), Seattle (Washington), as well as in Alberta and Ontario (Canada), Stockley Park and Cambridge (United Kingdom), Australia, New Zealand, Austria, Belgium, The Netherlands, France, Germany, Greece, Hong Kong (China), Ireland, Italy, Sweden, Poland, Portugal, Spain, Switzerland, and Turkey.
  • GILEAD SCIENCES INC

  • United States of America (US)
  • Company type: Corporate
  • Parent company: N/A
  • Chief Executive Officer (CEO): Mr Daniel Oday
  • CEO Total remuneration: 25.910.501,861
  • Website: www.gilead.com

Financial data

Number of employees

11,800
11,000
10,000
9,000

Revenue *

19.983
19.324
21.768
28.83

EBIT *

3.969
7.311
12.002
17.517

EBITDA *

5.218
8.559
13.074
18.615

* numbers are in millions

  • RepRisk Indicator (last month)*: 22

Social dialog

  • Transnational Corporate Agreement (TCA): N/A
  • Global Framework Agreement (GFA): N/A
  • Societas Europaea (SE): N/A
  • Bangladesh Accord: N/A

European Works Councils

  • EWC*: N/A

Standards and certifications

  • Global Compact:
  • N/A
  • CDP (Carbon Disclosure Project): N/A
  • Modern Slavery Statement: N/A
  • Transparency Index: N/A
  • SA8000 Social Accountability: N/A
  • Integrated report: N/A
  • ISO26000: N/A
  • OECD Guidelines: N/A
  • Social Development Goals (SDGs): N/A

Global Reporting Initiative certification*

  • Global Reporting Initiative standards: N/A
  • Global Reporting Initiative GRI G4: N/A

Other company declarations

  • Corporate Social Responsability:
    N/A
  • Accessibility: N/A

Other resources

Policies

  • Training policy: N/A
  • Policy to protect the right to health and safety in the workplaces where the company operates: N/A
  • Policy to protect the right to health and safety in the workplaces in the supply chain: N/A
  • Diversity policy: N/A

Universal declarations

Declarations and treaties recognised by the country where the company has its registered office

  • Universal Declaration of Human Rights:
  • European Convention on Human Rights (ECHR):
  • Charter of Fundamental Rights of CDFL Workers (Strasbourg Charter 1989):
  • Charter of Fundamental Rights of the European Union EU CFR (Nice Charter 2000):
  • Treaty on the Functioning of the European Union TFEU:
  • Registered office in an OECD country:
  • ILO C029 - Forced Labour Convention, 1930 (No. 29):
  • ILO C087 - Freedom of Association and Protection of the Right to Organise Convention, 1948 (No. 87):
  • ILO C098 - Right to Organise and Collective Bargaining Convention, 1949 (No. 98):
  • ILO C100 - Equal Remuneration Convention, 1951 (No. 100):
  • ILO C105 - Abolition of Forced Labour Convention, 1957 (No. 105):
  • ILO C111 - Discrimination (Employment and Occupation) Convention, 1958 (No. 111):
  • ILO C138 - Minimum Age Convention, 1973 (No. 138):
  • ILO C182 - Worst Forms of Child Labour Convention, 1999 (No. 182):

Directives applied in the company offices in EU 27

  • D. 80/987/EEC: N/A
  • D. 89/391/EEC: N/A
  • D. 98/59/EC: N/A
  • D. 2000/43/EC: N/A
  • D. 2000/78/EC: N/A
  • D. 2001/23/EC: N/A
  • Council D. 2001/86/EC: N/A
  • D. 2002/14/EC: N/A
  • D. 2002/73/EC: N/A
  • Council D. 2003/72/EC: N/A
  • EP and Council D. 2005/56/EC: N/A
  • D. 2009/38/EC: N/A
  • D. 2004/25/EC: N/A
  • D. 2011/35/EU: N/A

Presence in main rankings

  • Global 100 Most Sustainable Corporations: N/A
  • Global CSR Rep Trak 100: N/A
  • BrandZ Top 100 Most Valuable US Brands: N/A
  • The Worlds Best Multinational Workplaces: N/A
  • The Gartner Supply Chain Top 25: N/A
  • The Worlds Most Innovative Companies: N/A
  • The Diversity Inc Top 50 Companies: N/A
  • Best Global Websites: N/A
  • Green Ranking Global Top 500: N/A
  • Green Ranking Global Top 100: N/A

Latest news about gilead sciences inc

9 March 2020 - 12:00

35 vaccini candidati contro la Covid-19

Ci sarebbero 35 i vaccini candidati contro la Covid-19 in tutto il mondo. Qualche settimana fa erano dieci in meno. Tuttavia molti studi sono ancora in fase preclinica e i dettagli sono ancora poco chiari. La corsa all’oro del 2020, comunque, è contrassegnata anche a colpi mediatici piuttosto rilevanti dato che sempre più aziende annunciano lavori sul vaccino contro il nuovo coronavirus o, come nel caso dell’azienda americana Moderna (una delle prima ad essersi messa al lavoro) di essere vicino alla soluzione.

9 March 2020 - 12:00

These nine companies are working on coronavirus treatments or vaccines — here’s where things stand

The list includes Gilead Sciences Inc. and Moderna Inc. along with smaller biotechs

In the U.S., the companies that are initiating development have received funding from two organizations: the Biomedical Advanced Research and Development Authority (BARDA), which is a division of the Department of Health and Human Services, and the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health. Some companies have received funding from Coalition for Epidemic Preparedness Innovations (CEPI), a global organization based in Oslo. Other companies are funding trials by themselves or through partnerships with other life sciences companies.